Business
Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous UrticariaPresented Positive Follow-up Clinical Data from Investigator-Sponsored
About this update from Jasper Therapeutics, Inc.
[{"type":"text","content":"Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous UrticariaPresented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTRAnnounced Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta ThalassemiaStrengthened the Board of Directors and Management Team with Multiple AppointmentsRaised $101.4 Million Net Proceeds in January 2023 REDWOOD CITY, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended March 31, 2023, and provided a business update. “During our first quarter of 2023, we continued to execute on our expansion of briquilimab development to include chronic spontaneous urticaria, and took steps to strengthen our Board and management team with multiple key leadership appointments,” said Ronald Martell, President and Chief Executive Officer of Jasper. “We also secured substantial additional capital to support our development plans across the briquilimab franchise. During the quarter we also presented positive data at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, which, together with other recent data, continue to help establish the mechanistic and clinical proof-of-concept rationale for briquilimab’s mechanism of action, adding to our confidence in briquilimab and its potential to address a variety of patient populations by targeting c-Kit expressed on stem cells and mast cells. We look forward to carrying out our priority development programs for briquilimab as a c-Kit targeting therapeutic in chronic diseases and as a novel conditioning agent for stem cell transplant.” Highlights for Q1 2023 and Recent Weeks Key Appointments Made to the Board of Directors and Management Team Industry veteran Vishal Kapoor appointed to the Board of DirectorsDaniel Adelman, M.D. appointed as Acting Chief Med...